Rapid Micro Biosystems Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $35.2M+25.4% YoYTTM through 30 Jun 2026
Net Income -$51.2MTTM through 30 Jun 2026
Free Cash Flow -$40.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 3.0% |
| EBITDA Margin | -133.0% |
| Operating Margin | -141.1% |
| Net Margin | -145.6% |
Returns
-230.9%ROE
-37.0%ROA
Balance Sheet Health
Debt / Equity0.93x
Current Ratio3.31x
Net Debt-$19.4Mnet cash position
Cash & Equivalents$14.7M
Quality Metrics
Altman Z-Score-13.95
Piotroski F-Score2 / 9
FCF Margin-114.8%
Rule of 40-103.1
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $33.6M
Diluted EPS-$1.11TTMFY2025: $-1.05
Dividend
No dividend
Capital Allocation
R&D Spend$13.4M
Capex Intensity1.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product | $23.4M | +25.0% | |
| Service | $10.2M | +9.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.